LINCOLN PHARMACEUTICALS
Quarterly Results Analysis [Dec2023]
LINCOLN PHARMACEUTICALS Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 Audited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹146 Cr | ₹156 Cr | ₹136 Cr | ₹112 Cr | ₹134 Cr | ₹141 Cr | ₹123 Cr | ₹103 Cr |
Expenses | ₹117 Cr | ₹125 Cr | ₹115 Cr | ₹96 Cr | ₹107 Cr | ₹112 Cr | ₹107 Cr | ₹85 Cr |
Operating Income | ₹30 Cr | ₹31 Cr | ₹21 Cr | ₹17 Cr | ₹27 Cr | ₹29 Cr | ₹17 Cr | ₹17 Cr |
Other Income | ₹11 Cr | ₹9 Cr | ₹8 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹2 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
Depreciation | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
Profit Before Tax | ₹38 Cr | ₹37 Cr | ₹25 Cr | ₹17 Cr | ₹31 Cr | ₹32 Cr | ₹21 Cr | ₹17 Cr |
Profit After Tax | ₹28 Cr | ₹28 Cr | ₹19 Cr | ₹13 Cr | ₹22 Cr | ₹24 Cr | ₹15 Cr | ₹11 Cr |
EPS | ₹14.00 | ₹13.81 | ₹9.49 | ₹6.27 | ₹10.79 | ₹11.84 | ₹7.49 | ₹5.50 |
Industry Peers & Returns | 1W | 1M | 1Y |
LINCOLN PHARMACEUTICALS | 5.6% | -17.6% | 72.6% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
LINCOLN PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -6.12 % |
Y-o-Y | 9.48 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹146 Cr | -6.12 | |
Sep2023 | ₹156 Cr | 15.02 | |
Jun2023 | ₹136 Cr | 20.59 | |
Mar2023 | ₹112 Cr | -15.93 | |
Dec2022 | ₹134 Cr | -4.87 | |
Sep2022 | ₹141 Cr | 13.88 | |
Jun2022 | ₹123 Cr | 20.36 | |
Mar2022 | ₹103 Cr | - |
LINCOLN PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -4.78 % |
Y-o-Y | 10.87 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹30 Cr | -4.78 | |
Sep2023 | ₹31 Cr | 50.34 | |
Jun2023 | ₹21 Cr | 24.51 | |
Mar2023 | ₹17 Cr | -37.80 | |
Dec2022 | ₹27 Cr | -7.44 | |
Sep2022 | ₹29 Cr | 70.89 | |
Jun2022 | ₹17 Cr | -3.06 | |
Mar2022 | ₹17 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 1.40 % |
Y-o-Y | 1.25 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 20.25% | 1.40 | |
Sep2023 | 19.97% | 30.69 | |
Jun2023 | 15.28% | 3.24 | |
Mar2023 | 14.8% | -26.00 | |
Dec2022 | 20% | -2.68 | |
Sep2022 | 20.55% | 50.00 | |
Jun2022 | 13.7% | -19.46 | |
Mar2022 | 17.01% | - |
LINCOLN PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 1.39 % |
Y-o-Y | 29.73 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹28 Cr | 1.39 | |
Sep2023 | ₹28 Cr | 45.44 | |
Jun2023 | ₹19 Cr | 51.36 | |
Mar2023 | ₹13 Cr | -41.88 | |
Dec2022 | ₹22 Cr | -8.86 | |
Sep2022 | ₹24 Cr | 57.95 | |
Jun2022 | ₹15 Cr | 36.17 | |
Mar2022 | ₹11 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 8.01 % |
Y-o-Y | 18.50 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | 19.15 % | 8.01 | |
Sep2023 | 17.73 % | 26.46 | |
Jun2023 | 14.02 % | 25.51 | |
Mar2023 | 11.17 % | -30.88 | |
Dec2022 | 16.16 % | -4.15 | |
Sep2022 | 16.86 % | 38.65 | |
Jun2022 | 12.16 % | 13.12 | |
Mar2022 | 10.75 % | - |
LINCOLN PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 1.38 % |
Y-o-Y | 29.75 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹14 | 1.38 | |
Sep2023 | ₹13.81 | 45.52 | |
Jun2023 | ₹9.49 | 51.36 | |
Mar2023 | ₹6.27 | -41.89 | |
Dec2022 | ₹10.79 | -8.87 | |
Sep2022 | ₹11.84 | 58.08 | |
Jun2022 | ₹7.49 | 36.18 | |
Mar2022 | ₹5.5 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD